FDA approves Cipla’s generic Pulmicort Respules

FDA approves Cipla’s generic Pulmicort Respules

The Food and Drug Administration has approved Cipla’s generic of AstraZeneca’s Pulmicort Respules (budesonide inhalation suspension). The drug is indicated as a maintenance treatment for asthma and as prophylactic therapy in children ages 12 months to 8 years. The Mumbai-based Cipla said the drug was available immediately for shipment.

Картинки по запросу budesonide

Cipla’s generic will be available in dosage strengths of 0.25 mg/2 ml, 0.5 mg/2 ml and 1 mg/2ml. The product and its generics had U.S. sales of roughly $825 million for the 12 months ended September 2017, according to IQVIA data.

November 21, 2017

http://www.drugstorenews.com/

November 23, 2017 / Pharma News